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ABSTRACT
Objective: To evaluate the efficacy of tamsulosin in improving stent-related symptoms and 
quality of life (QoL) in patients with double-J (DJ) ureteric stents.
Subjects and Methods: A total of 136 patients were prospectively evaluated and distributed 
randomly in two groups. Group 1 was 69 patients with mean age 35 years (range 20-56) and Group 
2 was 67 patients with mean age 29 years (range 19-42). In Group 1, 43 cases had lower and 26 
had upper ureteric stones. In Group 2, 47 patients had lower and 20 had upper ureteric stones. 
Ureteroscopic lithotripsy was performed in all patients and a DJ stent (6F, 26cm) was inserted post-
operatively for about 4 weeks. Group 1 received tamsulosin 0.4mg orally once per day for 4 weeks.
The patients were evaluated with the International Prostate Symptom Score (IPSS) which consists 
of seven questions, three for irritative and four for obstructive symptoms. QoL was assessed 
with the QoL section of the IPSS and the short form 36 (SF-36) questionnaire which assesses 
patients in eight domains, including physical functioning, role limitations due to physical health 
or emotional disorders, vitality, mental health, social functioning, pain and general health.
Results: The IPSS irritative and obstructive symptom scores as well as the QoL scores were 
significantly lower in Group 1 than Group 2 (p<0.031). The SF-36 role limitation due to physical 
health and pain scores were significantly better in Group 1 than Group 2 (p<0.027). There were no 
significant differences in any other parameters. Five patients with tamsulosin (7.2%) had side-
effects in the form of headache and dizziness and the rest of the patients had no side-effects 
related to tamsulosin.
Conclusion: The administration of a selective alpha1 blocker, such as tamsulosin improves 
ureteric stent-related urinary symptoms after ureteroscopy and disintegration of ureteric stones.
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INTRODUCTION                                      
Ureteric stenting plays an important 
role in upper urinary tract drainage. 
Urgent indications include obstructive 
pyelonephritis and intolerable acute renal 
colic1. Safety indications following endoscopic 
procedures include ureteric perforation, edema, 
«steinstrasse», solitary kidney and transplant 
kidney2. In 1967 Zimskind et al3, used double-J 
(DJ) ureteric stenting postoperatively and other 
investigators used it especially after prolonged 
endoscopic procedures and in patients 
needing a second look ureteroscopy4. 
In 2006, Deliveliotis, et al. investigated 
the role of alpha-blockers for treating the 
symptoms related to DJ ureteric stenting. They 
found that treatment with 10 mg alfuzosin 
once daily for 4 weeks caused a decrease in 
the mean urinary symptom index, frequency 
of stent-related pain and improvement in the 
general health score index5.
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Group 1 Group 2 
Patients (n) 69 67
Age (years)
Mean 35 29 
Range 20-56 19-42
Gender
Males  44 50
Females 25 17
Stone location
Lower ureter 43 47
Upper ureter 26 20
Table 1: Charcteristics of the study groupsThe aim of this study was to evaluate the 
efficacy of tamsulosin in improving stent-
related symptoms and quality of life (QoL) in 
patients with post-operative DJ ureteric stents.
MATERIALS AND METHODS                
Between May 2007 and 2010 at Cairo 
University Hospital, 136 patients with 
ureteric stones were included in this study. 
They were evaluated by history taking, 
clinical examination, laboratory investigations 
and radiological investigations including 
intravenous urogram (IVU) or non-contrast 
spiral Computed Tomography (CT). The exclusion 
criteria were pregnancy, bleeding disorders, 
open surgery of the ureter, bilateral ureteric 
stents, long term use of alpha-blockers, 
history of prostatitis and chronic use of 
analgesics.
Ureteroscopic lithotripsy using a pneumatic 
lithotriptor with removal of stones was 
performed in all patients and a DJ ureteric 
stent (6F, 26cm) was inserted post-operatively 
for 4 weeks. The operative procedure was the 
same in all patients, who were divided into 
two groups.
Group 1 received tamsulosin 0.4mg orally 
once per day for Four weeks, ciprofloxacin 
500mg twice daily for Five days and 
paracetamol 400mg on demand. Group 2 
received paracetamol 400mg as analgesic on 
demand and ciprofloxacin 500 mg twice daily 
for Five days.
Follow-up consisted of plain X-ray film 
of the urinary tract (KUB) at 24 hours and 
at one week to exclude stone migration and 
assess the clearance of stones. Non-constrast 
CT or plain radiography was done after 
3 weeks to assess the stone free rate. The 
International Prostate Symptom Score (IPSS) 
was used to assess the patient’s symptoms 
postoperatively. The IPSS consists of seven 
questions, three for irritative and four for 
obstructive symptoms. Quality of life was 
assessed by the QoL section of the IPSS and 
short form 36 (SF-36)6 questionnaire.
The SF-36 assesses QoL in eight domains, 
including physical functioning, role limitations 
due to physical health or emotional disorders, 
vitality, mental health, social functioning, 
pain and general health6. Statistical analysis 
was done using the chi-square and t-test, 
as appropriate, p< 0.05 was considered 
statistically significant.
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Group 1 Group 2 P-value
Irritative symptoms 12.7 (8.3-15.7) 25.8 (22.1-30.1) P =0.031
Obstructive symptoms 3.8 (1.2-6.8) 12.9 (7.6-17.9) P< 0.001
Quality of life 5.1 (3.8-6.7) 8.8 (7.3-10.8) P< 0.001
SF-36
1. Physical functioning 2.5 (2.4-2.9) 2.24 (2.2-2.6) NS
2. Role limitations due to physical health 2.1 (1.7-2.5) 1.5 (1.2-1.9) P =0.0.027
3. Role limitations due to emotional problems 2.6 (1.7-2.5) 2.3 (1.9-2.4) NS
4. Vitality 2.3 (2.1-2.5) 2.1 (1.8-2.33) NS
5. Mental health 2.5 (2.4-2.84) 2.3 (2.1-2.5) NS
6. Social function 02.8 (2.7-3.2) 2.7 (2.3-3.1) NS
7. Pain 2.3 (2-2.5) 1.7 (1.4-2) P =0.003
8. General health 2.01 (1.7-2.30) 1.7 (1.4-2) NS
NS: not statistically significant
Table 2: International Prostatic Symptom Score (IPSS) and short form 36 (SF-36) scores in the study groups
RESULTS                                                       
The patients’ age, gender and ureteric 
stone location are shown in (Table 1).
The IPSS scores were significantly lower in 
Group 1 than Group 2 (Table 2). The SF-36 scores 
for role limitation due to physical health and 
pain were significantly better in Group 1 than 
Group 2 (Table 2). There were no significant 
differences in any other parameters.
Five patients treated with tamsulosin (7.2%) 
had side-effects in the form of headache and 
dizziness and the rest of the patients had no 
side-effects related to tamsulosin.
DISCUSSION                                                         
Ureteric stents are useful tools in urology 
but are known to be associated with significant 
side-effects. Several studies reported the 
symptoms related to ureteric stents, including 
frequency (50-60%), urgency (57-60%), 
dysuria (40%), incomplete emptying (76%).
flank (19-32%) and suprapubic pain (30%), 
incontinence and haematuria (25%)2,7-10. 
In a prospective randomized study, Deliveliotis 
et al evaluated the effect of alfuzosin versus 
placebo on symptoms and QoL in patients 
with indwelling ureteric catheters. They 
concluded that selective alpha-blockers such 
as alfuzosin improve stent-related symptoms 
and pain. In addition sexual function and 
general health were better preserved5.
Damiano et al performed a prospective 
randomized study comparing the efficacy of 
tamsulosin versus placebo for stent-related 
symptoms. The stent-related morbidity 
was evaluated with Urinary Symptom Score 
Questionnaire (USSQ) QoL questionaire. 
The authors reported that tamsulosin had 
positive effects on stent-related urinary 
symptoms and QoL11.
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In our study, all patients tolerated the 
ureteric stents for the 4 weeks postoperative 
period. The IPSS scores were significantly 
lower and the QoL scores were significantly 
better in patients who received tamsulosin. 
Five patients treated with tamsulosin (7.2%) 
had side-effects in the form of headache and 
dizziness and the rest had no side-effects 
related to tamsulosin.
CONCLUSION                                             
Placement of indwelling ureteric stents has 
become routine in the management of a variety of 
urinary tract diseases. Stent-related morbidity is a 
reality in the majority of patients. The administration 
of a selective alpha1-blocker, such as tamsulosin 
improves ureteric stent-related urinary symptoms 
after ureteroscopy and removal of ureteric stones.
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